Home > Newsletters > The QMN Weekly Bulletin > British Drugmaker Cited for cGMP, Misbranding Violations
The QMN Weekly Bulletin
Aug. 17, 2012 | Vol. 4 No. 33
British Drugmaker Cited for cGMP, Misbranding Violations
British drugmaker A Nelson has been cited in an FDA warning letter after an inspection found glass fragments in a batch of the company’s Clikpak drug vials.
Nelson had not identified a corrective and preventive action plan to reduce future occurrence, according to the July 26 warning letter, posted recently online. It also failed to determine if a potentially affected product was released for distribution.
Problems in A Nelson’s assembly process also caused some drugs to lack the correct amount of active ingredient, the FDA found during an inspection.
Don’t let your next inspection catch you unprepared! Every year the FDA tweaks its inspection processes and policies, and if you aren’t on board you might be warned next.
Get all the answers you need at FDAnews’ Seventh Annual FDA Inspections Summit.
The information you will hear comes directly from prominent FDA officials that know the business. After this conference, you’ll be well equipped to take on the next inspection the FDA throws your way. Register today!
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.